These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23747780)

  • 21. Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study.
    Alexopoulos D; Barampoutis N; Gkizas V; Vogiatzi C; Tsigkas G; Koutsogiannis N; Davlouros P; Hahalis G; Nylander S; Parodi G; Xanthopoulou I
    Clin Pharmacokinet; 2016 Mar; 55(3):359-67. PubMed ID: 26315810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to letter regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos K; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2013 Apr; 6(2):e29. PubMed ID: 23591428
    [No Abstract]   [Full Text] [Related]  

  • 23. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis.
    Alexopoulos D; Xanthopoulou I; Plakomyti TE; Goudas P; Koutroulia E; Goumenos D
    Am J Kidney Dis; 2012 Aug; 60(2):332-3. PubMed ID: 22658575
    [No Abstract]   [Full Text] [Related]  

  • 24. Letter by Grove and Kristensen regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
    Grove EL; Kristensen SD
    Circ Cardiovasc Interv; 2013 Apr; 6(2):e28. PubMed ID: 23591427
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial.
    Kubica J; Adamski P; Ostrowska M; Koziński M; Obońska K; Laskowska E; Obońska E; Grześk G; Winiarski P; Paciorek P
    Trials; 2015 Apr; 16():198. PubMed ID: 25925591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study.
    Montalescot G; Lassen JF; Hamm CW; Lapostolle F; Silvain J; ten Berg JM; Cantor WJ; Goodman SG; Licour M; Tsatsaris A; van't Hof AW
    Am Heart J; 2013 Apr; 165(4):515-22. PubMed ID: 23537967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The PEGASUS-TIMI 54 study].
    Tarantini G; D'Amico G; Parodi G; Musumeci G; Borghesi M
    G Ital Cardiol (Rome); 2015 Oct; 16(10):525-32. PubMed ID: 26444209
    [No Abstract]   [Full Text] [Related]  

  • 29. Ticagrelor: the first novel reversible P2Y(12) inhibitor.
    Htun WW; Steinhubl SR
    Expert Opin Pharmacother; 2013 Feb; 14(2):237-45. PubMed ID: 23268703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
    Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C
    J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons from platelet inhibition and patient outcomes.
    Held C
    Curr Opin Cardiol; 2012 Jul; 27(4):355-60. PubMed ID: 22565140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [ATLANTIC trial and feasibility of early administration of ticagrelor in myocardial infarction].
    Kanorskiĭ SG
    Kardiologiia; 2014; 54(11):65-9. PubMed ID: 25902661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
    Orban M; Riegger J; Joner M; Tada T; Okrojek R; Hausleiter J; Kastrati A; Massberg S; Sibbing D
    Platelets; 2012; 23(5):395-8. PubMed ID: 22671583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial?
    Serebruany VL
    Am Heart J; 2011 Jan; 161(1):1-4. PubMed ID: 21167333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ticagrelor in the Real World: The Midland Regional Cardiac Network Experience.
    Lee M; Green SA; Cherian T; Devlin G
    N Z Med J; 2015 Nov; 128(1425):110-1. PubMed ID: 26905996
    [No Abstract]   [Full Text] [Related]  

  • 37. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
    Cheng JW
    Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
    Storey RF; Becker RC; Harrington RA; Husted S; James SK; Cools F; Steg PG; Khurmi NS; Emanuelsson H; Lim ST; Cannon CP; Katus HA; Wallentin L
    Am J Cardiol; 2011 Dec; 108(11):1542-6. PubMed ID: 21890085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients.
    Alexopoulos D; Xanthopoulou I; Siapika A; Tsoni E; Stavrou K; Theodoropoulos KC; Davlouros P
    Int J Cardiol; 2013 Sep; 168(1):629-30. PubMed ID: 23434008
    [No Abstract]   [Full Text] [Related]  

  • 40. Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?
    Vannini L; Muro A; Sanchis J; Ortiz-Pérez JT; Flores Umanzor E; López-Lereu MP; Badimon L; Sabaté M; Brugaletta S
    Int J Cardiol; 2016 Nov; 223():226-227. PubMed ID: 27541661
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.